Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.

Ingrid CostedoatMartin WallaertAurelie GaultierRobin VasseurClelia VanhaeckeManuelle ViguierCharles CordeletteAlexandre DenoyerMarie-Christine Ferrier le BouëdecAdrien CoutuMarie LamiauxThi Ha Châu TranJean Philippe LacourValerie ElmalehFlorence TetartJulie GueudryMarie TauberFrancoise Giordano-LabadieMyriam CassagneAudrey NosbaumCoralie OuilhonMarie JachietRamin TadayoniFrédéric DezoteuxDelphine Staumont-SalleJulien BouleauPierre LabaletteSerge DoanAngele SoriaBruno MortemousqueJulien Seneschal Sébastien Barbarotnull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.

Keyphrases

atopic dermatitis
high glucose
end stage renal disease
newly diagnosed
ejection fraction
diabetic rats
cross sectional
patient reported outcomes
stress induced